TR200103236T2 - Ftalazin türevlerinin kullanımı - Google Patents

Ftalazin türevlerinin kullanımı

Info

Publication number
TR200103236T2
TR200103236T2 TR2001/03236T TR200103236T TR200103236T2 TR 200103236 T2 TR200103236 T2 TR 200103236T2 TR 2001/03236 T TR2001/03236 T TR 2001/03236T TR 200103236 T TR200103236 T TR 200103236T TR 200103236 T2 TR200103236 T2 TR 200103236T2
Authority
TR
Turkey
Prior art keywords
phthalazine derivatives
parp
inhibitors
homologous enzymes
phthalazine
Prior art date
Application number
TR2001/03236T
Other languages
English (en)
Inventor
Lubisch Wilfried
Sadowski Jens
Kock Michael
H�Ger Thomas
Original Assignee
Basf Aktiengeselschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengeselschaft filed Critical Basf Aktiengeselschaft
Publication of TR200103236T2 publication Critical patent/TR200103236T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus ftalazin türevlerinin enzim poli(ADP-riboz)polimeraz veya PARP (EC 2.4.2.30) inhibitörleri olarak kullanimi;PARP-homolog enizmlerin inhibitörleri olarak kullanimi ile ilgilidir ve özellikle bu ftalzin türevleri ayrica PARP-homolog enzimlerinin selektif inhibisyonunu göstermektedir.
TR2001/03236T 1999-05-11 2000-05-03 Ftalazin türevlerinin kullanımı TR200103236T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19921567A DE19921567A1 (de) 1999-05-11 1999-05-11 Verwendung von Phthalazine-Derivaten

Publications (1)

Publication Number Publication Date
TR200103236T2 true TR200103236T2 (tr) 2004-08-23

Family

ID=7907632

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03236T TR200103236T2 (tr) 1999-05-11 2000-05-03 Ftalazin türevlerinin kullanımı

Country Status (20)

Country Link
US (1) US6903098B1 (tr)
EP (1) EP1231982B1 (tr)
JP (1) JP2003502286A (tr)
KR (1) KR20020000642A (tr)
CN (1) CN1399573A (tr)
AT (1) ATE357272T1 (tr)
AU (1) AU5064000A (tr)
BG (1) BG106056A (tr)
BR (1) BR0010428A (tr)
CA (1) CA2372704A1 (tr)
CZ (1) CZ20014038A3 (tr)
DE (2) DE19921567A1 (tr)
ES (1) ES2284499T3 (tr)
HU (1) HUP0202477A3 (tr)
IL (1) IL146148A0 (tr)
NO (1) NO20015462L (tr)
PL (1) PL352150A1 (tr)
SK (1) SK286676B6 (tr)
TR (1) TR200103236T2 (tr)
WO (1) WO2000067734A2 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510359A (ja) * 1999-10-01 2003-03-18 スミスクライン・ビーチャム・コーポレイション 化合物および方法
CA2404128C (en) * 2000-03-20 2011-01-04 Peter Literati Nagy Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003015785A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
CA2482806A1 (en) * 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1527183B1 (de) 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
CA2500888C (en) 2002-10-01 2010-07-13 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
ES2376166T3 (es) 2002-11-22 2012-03-09 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal.
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2006094976A2 (en) 2005-03-08 2006-09-14 Basf Plant Science Gmbh Expression enhancing intron sequences
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
RS53196B (en) * 2006-12-28 2014-06-30 Abbvie Inc. INHIBITORI POLI (ADP-RIBOZA) POLIMERAZE
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009064444A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2250282A4 (en) * 2008-02-04 2011-05-18 Bipar Sciences Inc METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES
KR101846029B1 (ko) 2008-08-06 2018-04-06 메디베이션 테크놀로지즈 엘엘씨 폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제
NZ592719A (en) * 2008-10-07 2012-09-28 Astrazeneca Uk Ltd PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
BR112012012588B1 (pt) 2009-11-27 2019-03-26 Basf Plant Science Company Gmbh Endonuclease, método para recombinação homóloga de polinucleotídeos e método para mutação direcionada de polinucleotídeos
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
BR112012012444A2 (pt) 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor, organismo não humano, método para fornecer uma endonuclease quimérica, método para recombinação homóloga de polinucleotídeos, método para mutação alvejada de polinucleotídeosa e método para recombinação homóloga ou mutação alvejada"
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
EP2533640B1 (en) * 2010-02-08 2016-09-28 Medivation Technologies, Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN103325380B (zh) 2012-03-23 2017-09-12 杜比实验室特许公司 用于信号增强的增益后处理
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CA3041843A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116471A (ja) 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd ４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
KR100189865B1 (ko) 1994-08-09 1999-06-01 나이또 하루오 축합 피리다진계 화합물
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
DE69803750T2 (de) * 1997-12-02 2002-09-12 Reddy S Res Foundation Andhra Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
CO5070700A1 (es) 1998-06-05 2001-08-28 Basf Ag Genes novedosos de (adp-ribosa) polimerasa
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4

Also Published As

Publication number Publication date
CA2372704A1 (en) 2000-11-16
IL146148A0 (en) 2002-07-25
BR0010428A (pt) 2002-04-30
NO20015462D0 (no) 2001-11-08
HUP0202477A2 (hu) 2002-12-28
CZ20014038A3 (cs) 2002-06-12
JP2003502286A (ja) 2003-01-21
ES2284499T3 (es) 2007-11-16
AU5064000A (en) 2000-11-21
HUP0202477A3 (en) 2003-02-28
CN1399573A (zh) 2003-02-26
EP1231982B1 (de) 2007-03-21
WO2000067734A2 (de) 2000-11-16
PL352150A1 (en) 2003-07-28
US6903098B1 (en) 2005-06-07
BG106056A (en) 2002-06-28
SK286676B6 (sk) 2009-03-05
DE50014190D1 (de) 2007-05-03
WO2000067734A3 (de) 2002-06-20
ATE357272T1 (de) 2007-04-15
NO20015462L (no) 2001-11-08
DE19921567A1 (de) 2000-11-16
KR20020000642A (ko) 2002-01-05
SK15952001A3 (sk) 2002-08-06
EP1231982A2 (de) 2002-08-21

Similar Documents

Publication Publication Date Title
TR200103236T2 (tr) Ftalazin türevlerinin kullanımı
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
TR200103216T2 (tr) Pirimidinon bileşimleri
IL144032A0 (en) Serine protease inhibitors
EP1818396A3 (en) Alpha-Amylase variants
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
CA2288948A1 (en) Modified arginine deiminase
CA2335153A1 (en) Enzyme stabilization by cationic surfactants
WO2005058798A8 (en) Compounds having selective cytochrome p450rai-1 or selective cytochrome p450rai-2 inhibitory activity and methods of obtaining the same
HK1044543A1 (en) Beta-secretase enzyme compositions and methods.
ATE238415T1 (de) Feste phytase-zusammensetzungen
DE60132113D1 (de) Stabilisierte zusammensetzung zum enzymatischen entfernen von wundgrind
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
PT1147103E (pt) Fenantridina-n-oxidos com actividade inibitoria de pde-iv
DE59009945D1 (de) Mittel zur hemmung von hiv-proteasen.
ATE260246T1 (de) Selektive inhibitoren des urokinase-plasminogen aktivators
GB2324091B (en) Metalloproteinase inhibitors
ATE256673T1 (de) Chirale phenyldihydrofuranone als pde-iv inhibitoren
WO2001060986A3 (en) Esterase enzymes having selective activity
AU2001260314A1 (en) Method for selecting enzyme inhibitors
BG105252A (en) Isoquinolines as urokinase inhibitors
PT1196606E (pt) Enzima litica
ATE290878T1 (de) Inhibierung von invasiver remodulierung
WO2000021547A3 (de) Beeinflussung von hyperaktiven t-zellen durch proteolytische enzyme